GENFIT to Present Update on Scientific and Corporate Progress at The Liver Meeting 2023 - Seite 2

Interim data disclosure for the ELATIVE Phase 3 trial evaluating elafibranor in PBC

Ipsen will present the full 52-week results from the ELATIVE Phase 3 trial evaluating elafibranor in Primary Biliary Cholangitis (PBC) in a late-breaking oral session (Abstract #484, Monday, November 13 at 4.45pm ET).

Following the late-breaker presentation of the ELATIVE Phase 3 interim results, Ipsen plans to host a conference call for analysts and investors on Tuesday November 14 at 4.00pm CET / 10.00am ET. Joining the event will be Dr. Christopher Bowlus, Lena Valente Professor and Chief of the Division of Gastroenterology and Hepatology at the University of California Davis School of Medicine, presenter of the late-breaker session.

GENFIT’s NASH diagnostics technology presentations

GENFIT will present new data on its NASH diagnostics technology, including:

• Performances of NIS2+ and other non-invasive tests for the detection of at-risk NASH along the BMI (Body Mass Index) spectrum (Poster #2089-A)
• The impact of BMI on NIS2+ and established non-invasive tests for the evaluation of non-alcoholic liver disease (15’ Oral Presentation #238, Pr. Sven Francque)
• The sequential use of FIB-4 and NIS2+ for an accurate detection of non-cirrhotic at-risk NASH patients for enrollment in NASH clinical trials (Poster of Distinction #2100-A)²
• NIS2-mice, an adaptation of the clinical NIS2+ diagnostic test for the detection of NAS ≥4 & F ≥2 in GAN diet-induced obese and biopsy confirmed mouse model of NASH with advanced fibrosis (Poster #2082-A, in collaboration with Gubra)

LabCorp Product Theater
LabCorp, GENFIT’s commercial partner for its diagnostics technology, will also host a Product Theater, highlighting recent data for NIS4 and NIS2+ technology and their use in patient management, as well as in clinical trials. A 30-minute presentation will be held with Dr. Stephen Harrison speaking on Monday, November 13 from 1:30-2:00 PM ET at the Plaza Level exhibit hall (Product Theater #2).

END

ABOUT AASLD

AASLD is the leading organization of scientists and health care professionals committed to preventing and curing liver disease. AASLD fosters research that leads to improved treatment options for millions of liver disease patients. They advance the science and practice of hepatology through educational conferences, training programs, professional publications, and partnerships with government agencies and sister societies.